Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Gross Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Gross Margin data on record, last reported at 99.0% in Q4 2025.

  • For Q4 2025, Gross Margin rose 437.0% year-over-year to 99.0%; the TTM value through Dec 2025 reached 99.0%, up 251.0%, while the annual FY2025 figure was 99.0%, 251.0% up from the prior year.
  • Gross Margin reached 99.0% in Q4 2025 per LCTX's latest filing, down from 99.86% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.86% in Q3 2025 and bottomed at 56.61% in Q3 2021.
  • Average Gross Margin over 5 years is 90.66%, with a median of 95.01% recorded in 2023.
  • Peak YoY movement for Gross Margin: plummeted -2553bps in 2021, then surged 2985bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 56.61% in 2021, then surged by 67bps to 94.67% in 2022, then dropped by -5bps to 89.58% in 2023, then rose by 6bps to 94.63% in 2024, then increased by 5bps to 99.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 99.0% in Q4 2025, 99.86% in Q3 2025, and 98.59% in Q2 2025.